Brief: BioArctic Partner Submits Leqembi sBLA To FDA

BioArctic AB

02/04/2024 07:15

April 2 (Reuters) - BioArctic AB  BIOAb.ST :
    * SAID ON MONDAY THAT CO'S PARTNER EISAI ANNOUNCED IT HAS
SUBMITTED SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR
MONTHLY LECANEMAB-IRMB (U.S. BRAND NAME: LEQEMBI) INTRAVENOUS
MAINTENANCE DOSING TO THE U.S. FDA


        
 Source text for Workspace:  urn:newsml:reuters.com:*:nWkr39n7jl
 Further company coverage:  BIOAb.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))